Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To show non-inferiority in the efficacy of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2 puffs bid), based on the mean change in the pre-morning dose value of forced expiratory volume in the first second (FEV1) from baseline (end of run in period) to the end of the 12 week treatment period.
Critère d'inclusion
- Asthma bronchial